{
    "organizations": [],
    "uuid": "4f092f6837808e2770a95227010a7aa2f70f9006",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biohaven-says-expects-topline-resu/brief-biohaven-says-expects-topline-results-from-phase-3-trial-with-rimegepant-zydis-odt-in-q4-idUSASB0C8WZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Biohaven Says Expects Topline Results From Phase 3 Trial With Rimegepant Zydis ODT In Q4​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:\n* BIOHAVEN ENROLLS FIRST PATIENT IN PHASE 3 CLINICAL TRIAL TO EVALUATE RIMEGEPANT ZYDIS® ODT IN THE ACUTE TREATMENT OF MIGRAINE\n* BIOHAVEN - CONTINUES TO EXPECT TOPLINE RESULTS FROM TWO PHASE 3 TRIALS EXAMINING EFFICACY OF RIMEGEPANT 75 MG ORAL TABLET VERSUS PLACEBO BY END OF Q1 2018​\n* BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD SAYS ‍EXPECTS TOPLINE RESULTS FROM PHASE 3 TRIAL WITH RIMEGEPANT ZYDIS(®) ODT IN Q4 OF 2018​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-06T16:07:00.000+02:00",
    "crawled": "2018-03-06T10:57:30.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "biohaven",
        "pharmaceutical",
        "holding",
        "company",
        "ltd",
        "biohaven",
        "enrolls",
        "first",
        "patient",
        "phase",
        "clinical",
        "trial",
        "evaluate",
        "rimegepant",
        "odt",
        "acute",
        "treatment",
        "migraine",
        "biohaven",
        "continues",
        "expect",
        "topline",
        "result",
        "two",
        "phase",
        "trial",
        "examining",
        "efficacy",
        "rimegepant",
        "mg",
        "oral",
        "tablet",
        "versus",
        "placebo",
        "end",
        "q1",
        "biohaven",
        "pharmaceutical",
        "holding",
        "company",
        "ltd",
        "say",
        "topline",
        "result",
        "phase",
        "trial",
        "rimegepant",
        "zydis",
        "odt",
        "q4",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}